1. Home
  2. OGE vs PRAX Comparison

OGE vs PRAX Comparison

Compare OGE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OGE Energy Corp

OGE

OGE Energy Corp

HOLD

Current Price

$49.37

Market Cap

8.8B

Sector

Utilities

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$327.15

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGE
PRAX
Founded
1902
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
9.6B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
OGE
PRAX
Price
$49.37
$327.15
Analyst Decision
Buy
Strong Buy
Analyst Count
9
15
Target Price
$47.33
$572.13
AVG Volume (30 Days)
1.5M
375.4K
Earning Date
05-21-2026
05-12-2026
Dividend Yield
3.46%
N/A
EPS Growth
5.94
N/A
EPS
2.32
N/A
Revenue
$3,260,100,000.00
N/A
Revenue This Year
$2.45
N/A
Revenue Next Year
$0.96
$1,840.20
P/E Ratio
$21.16
N/A
Revenue Growth
9.21
N/A
52 Week Low
$40.80
$26.70
52 Week High
$49.18
$354.87

Technical Indicators

Market Signals
Indicator
OGE
PRAX
Relative Strength Index (RSI) 83.40 53.37
Support Level $42.94 $290.36
Resistance Level N/A N/A
Average True Range (ATR) 1.02 18.77
MACD 0.28 -1.12
Stochastic Oscillator 97.05 55.40

Price Performance

Historical Comparison
OGE
PRAX

About OGE OGE Energy Corp

OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: